TY - JOUR
T1 - Viloxazine in the treatmentof depressive neurosis
T2 - A controlled clinical study with doxepin and placebo
AU - McEvoy, J. P.
AU - Sheridan, W. F.
AU - Stewart, W. R.C.
PY - 1980
Y1 - 1980
N2 - In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.
AB - In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.
UR - http://www.scopus.com/inward/record.url?scp=0018911373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018911373&partnerID=8YFLogxK
U2 - 10.1192/bjp.137.5.440
DO - 10.1192/bjp.137.5.440
M3 - Article
C2 - 7008890
AN - SCOPUS:0018911373
SN - 0007-1250
VL - 137
SP - 440
EP - 443
JO - British Journal of Psychiatry
JF - British Journal of Psychiatry
IS - 5
ER -
